TrialNature communications2024

Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial.

Hongyu Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.